Literature DB >> 23148371

Fingerprinting acute leukemia: DNA methylation profiling of B-acute lymphoblastic leukemia.

Luisa Cimmino1, Iannis Aifantis.   

Abstract

In this issue of Cancer Discovery, Geng and colleagues report on their use of a combination of promoter cytosine methylation profiling with gene expression and ChIP sequencing to elucidate molecular signatures of adult B-acute lymphoblastic leukemia patient samples with BCR-ABL1, E2A-PBX1, and MLL rearrangements. The unique epigenetic and gene expression signatures of these clinically unfavorable B-ALL subtypes identify novel biomarkers and provide a strong rationale for repurposing existing therapies to treat these molecularly distinct diseases. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23148371      PMCID: PMC4307588          DOI: 10.1158/2159-8290.CD-12-0435

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  14 in total

Review 1.  Targeting epigenetic programs in MLL-rearranged leukemias.

Authors:  Kathrin M Bernt; Scott A Armstrong
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells.

Authors:  Richard Bayly; Luan Chuen; Richard A Currie; Brandy D Hyndman; Richard Casselman; Gerd A Blobel; David P LeBrun
Journal:  J Biol Chem       Date:  2004-10-26       Impact factor: 5.157

Review 3.  Treatment of acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; William E Evans
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

Review 4.  Advances in interleukin 2 receptor targeted treatment.

Authors:  J C Morris; T A Waldmann
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 5.  Advances in understanding cancer genomes through second-generation sequencing.

Authors:  Matthew Meyerson; Stacey Gabriel; Gad Getz
Journal:  Nat Rev Genet       Date:  2010-10       Impact factor: 53.242

Review 6.  FLT3 inhibitors: a story of the old and the new.

Authors:  Amir Fathi; Mark Levis
Journal:  Curr Opin Hematol       Date:  2011-03       Impact factor: 3.284

7.  Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

Authors:  P Vigneri; J Y Wang
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

8.  A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.

Authors:  Leandro C Cerchietti; Shao Ning Yang; Rita Shaknovich; Katerina Hatzi; Jose M Polo; Amy Chadburn; Steven F Dowdy; Ari Melnick
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

9.  CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.

Authors:  Mithat Gönen; Zhuoxin Sun; Maria E Figueroa; Jay P Patel; Omar Abdel-Wahab; Janis Racevskis; Rhett P Ketterling; Hugo Fernandez; Jacob M Rowe; Martin S Tallman; Ari Melnick; Ross L Levine; Elisabeth Paietta
Journal:  Blood       Date:  2012-08-01       Impact factor: 22.113

10.  Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.

Authors:  Amir T Fathi; Omar Abdel-Wahab
Journal:  Adv Hematol       Date:  2011-06-26
View more
  1 in total

Review 1.  The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia.

Authors:  Szymon Janczar; Karolina Janczar; Agata Pastorczak; Hani Harb; Adam J W Paige; Beata Zalewska-Szewczyk; Marian Danilewicz; Wojciech Mlynarski
Journal:  Cancers (Basel)       Date:  2017-01-03       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.